Ciara Kennedy, Amplyx CEO
July 20, 2020 09:38 AM EDT
R&D

Am­plyx touts up­beat read­out from a small PhII study for lead an­ti­fun­gal

Max Gelman

Senior Editor

Am­plyx, a biotech fo­cused on treat­ing pa­tients with com­pro­mised im­mune sys­tems, is tout­ing its lead pro­gram fol­low­ing a Phase II study.

The

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times